Microbot Medical Inc.

Microbot Medical Inc. announced the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026. The company reported significant growth, with revenue increasing by over 100% compared to the previous quarter, driven by the Full Market Release of its LIBERTY Endovascular Robotic System and expanded customer adoption. Key achievements include market expansion into new states, increased utilization among existing customers, a partnership with Lovell Government Services, and regulatory clearance in Israel.

Microbot Medical Inc. reported a net loss of $(5.6) million for the three months ended June 30, 2026, compared to $(3.5) million in the prior year. The company commenced revenue recognition, generating $241 thousand in Q2 2026 and $346 thousand for the six months ended June 30, 2026. As of June 30, 2026, the company held $64.2 million in marketable securities and stated it has sufficient funds for over twelve months of operations, despite increased operating cash burn.

Microbot Medical Inc. announced an increase in the annual base salary for its Chief Financial Officer, Rachel Vaknin. Effective August 1, 2026, her salary will be NIS 864,000, which is equivalent to $288,000. Additionally, Ms. Vaknin will receive a special bonus of $21,000 for the first half of 2026.

Microbot Medical Inc. announced that its CEO, Harel Gadot, will present at the Society of Robotic Surgery (SRS) annual meeting from July 23-26, 2026. He will discuss the endovascular robotic market and emerging technologies, highlighting the company's LIBERTY® Endovascular Robotic System, which received FDA clearance less than a year ago and is seeing growing adoption. The company also recently won the Innovative Start-Up Award from Surgical Robotics Technology.

Microbot Medical Inc. will participate in the Society of Robotic Surgery (SRS) annual meeting from July 23-26, 2026, where CEO Harel Gadot will present on the endovascular robotic market. This marks the second time endovascular robotics is featured at SRS, highlighting the growing importance of this segment, especially with the LIBERTY System's recent FDA clearance and adoption. The company also recently received the Innovative Start-Up Award from Surgical Robotics Technology for its groundbreaking technology.

Microbot Medical Inc. announced significant operational growth for the second quarter ended June 30, 2026, reporting over 100% growth in both revenue and new customers compared to the first quarter. This performance follows the successful commencement of the Full Market Release of its LIBERTY Endovascular Robotic System in April. The company is expanding its U.S. sales footprint, planning to enter international markets, and has secured a second manufacturing site to support rising demand.

Microbot Medical Inc. has signed a Letter of Agreement with Sanmina Corporation, a global integrated manufacturing solutions provider, to manufacture its LIBERTY Endovascular Robotic System. This partnership aims to expand manufacturing capacity to meet increasing demand in the U.S. and international markets, including recent clearance in Israel and progress towards CE Mark. The company expects the agreement to improve operating efficiencies, lower costs, and expand gross margins, while also providing a second manufacturing site.

Microbot Medical Inc. announced it has won the Innovative Start-Up Award from Surgical Robotics Technology for its LIBERTY Endovascular Robotic System. This award recognizes companies with outstanding technological and commercial progress through groundbreaking technologies. The LIBERTY system, which is FDA-cleared and remotely operated, is being adopted by leading academic centers across several states, further validating its impact on robotic-assisted endovascular care.

Microbot Medical Inc. announced that a globally recognized academic center in Pennsylvania has adopted its LIBERTY® Endovascular Robotic System, marking the first adoption in the state. This expands the company's presence to seven states across the Eastern U.S. The company also plans to expand its sales territory to the West Coast and into U.S. federal healthcare systems.

Microbot Medical Inc. announced a vendor agreement with Lovell Government Services to expand access for its LIBERTY® Endovascular Robotic System. This partnership will enable the sale of the LIBERTY® System to over 2,000 U.S. government facilities, including those under the Veterans Health Administration, Military Health System, and Indian Health Service. Lovell Government Services will serve as the Company's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, streamlining procurement and helping government agencies meet SDVOSB goals.